Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

Inclusion Criteria: * Provision of written signed informed consent prior to any study specific procedures; * Female subjects with histologically diagnosed relapsed high-grade serous or high-grade endometrioid ovarian cancer; * At least 1 lesion (measurable by RECIST v1.1) that can be accurately assessed at baseline by computed tomography (CT)/magnetic resonance imaging (MRI) and is suitable for repeated assessment; * Subjects must have received at least 1 prior platinum-based line of chemotherapy for ovarian cancer. Note: There is no limit on the number of lines of chemotherapy; * Subjects must be partially-platinum-sensitive (defined as progression 6 to 12 months after the end of the last platinum-based chemotherapy) or platinum sensitive (defined as progression \> 12 months after the end of the last platinum-based chemotherapy); * Subjects must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment; * ECOG performance status 0 to 1; * Subjects must have a life expectancy greater than or equal to 16 weeks; * Postmenopausal or evidence of non-childbearing status for women of childbearing potential: negative urine or serum pregnancy test within 28 days of study treatment and confirmed prior to treatment on Day 1; * Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations; and * Formalin fixed, paraffin embedded tumor sample (…